Features How it works Pricing FAQ News Compounds Glossary Calculator Converter
Home › News
Updated every other day

Latest Peptide News

Original reporting on the peptide industry — FDA actions and compounding decisions, supply and shortage changes, new clinical trial results, and peer-reviewed research on the peptides people actually track. Published every other day, sourced to primary documents, and written for people managing a protocol rather than for clinicians.

Browse by peptide

Semaglutide24 articlesTirzepatide19 articlesRetatrutide6 articlesGLP-1 & Incretins32 articlesCompounding & Supply6 articlesSafety & Regulation18 articles

Peptide News

Pregnant woman checks weight in modern bathroom. Reflecting on health and motherhood. — Illustration accompanying a report on GLP-1 non-responders and new SELECT trial weight-loss analyses
September 26, 2026

GLP-1 Non-Responders: New SELECT Analyses and a Nature Report on Why Response Varies

A Nature news feature published this week puts a spotlight on GLP-1 non-responders — the people who take semaglutide or tirzepatide and see little weight change — while two fresh analyses of the SELECT trial dig into who loses the most and whether weight loss is what drives the drugs' cardiovascular benefit. For anyone tracking a GLP-1 protocol, the research reframes what a plateau actually means.

GLP-1 & IncretinsSemaglutideTirzepatide
Doctor performing ultrasound scan on patient in modern clinic. — Illustration for a GLP-1 muscle loss study using DXA body composition scans and strength testing
September 23, 2026

GLP-1 Muscle Loss Study Will Track DXA Scans and Grip Strength

An observational GLP-1 muscle loss study posted to ClinicalTrials.gov on September 22 will measure body composition with DXA scans plus physical function tests in adults already starting GLP-1 receptor agonist therapy. It lands alongside a new review in Maturitas that flags muscle health as one of the open questions for semaglutide in postmenopausal women.

GLP-1 & IncretinsSemaglutideTirzepatide
Close-up of a woman in underwear measuring her waist with a tape measure, fitness concept. — Illustration accompanying coverage of a tirzepatide abdominal fat study from the SURMOUNT-J trial
September 20, 2026

Tirzepatide Abdominal Fat Study From SURMOUNT-J Hits PubMed

A tirzepatide abdominal fat study drawn from the SURMOUNT-J trial has been indexed in PubMed, reporting changes in abdominal adiposity and their associations with metabolic health markers in Japanese participants with obesity disease. It lands alongside two newly posted registry records comparing weekly incretin drugs head to head.

TirzepatideGLP-1 & IncretinsSemaglutide
Detailed view of an optical phoropter in a modern eye clinic, used for testing vision clarity. — Illustration accompanying a report on tirzepatide eye side effects described in a new eyelid case series
September 19, 2026

Tirzepatide Eye Side Effects Reported in New Stye Case Series

A newly indexed case series in JCEM Case Reports documents simultaneous and recurrent eyelid styes and chalazia in people taking tirzepatide, putting a rarely discussed category of tirzepatide eye side effects into the published literature. The report is small and observational, but it arrives alongside several other new case-level safety papers across the GLP-1 class.

TirzepatideSafety & RegulationGLP-1 & Incretins
Mature woman working out on a leg press machine in a gym, promoting active and healthy lifestyle. — Illustration accompanying coverage of the tirzepatide muscle loss trial testing resistance training during incretin therapy
September 18, 2026

Tirzepatide Muscle Loss Trial Tests Resistance Training in 150 Adults

A newly listed tirzepatide muscle loss trial in Germany will measure contractile thigh muscle volume in 150 adults on the dual GIP/GLP-1 agonist, randomising them to resistance training or standard care. It lands alongside two new journal reviews on nutrient intake and nutritional deficiencies during GLP-1 therapy, and together they mark how quickly lean mass and nutrition have moved to the centre of incretin research.

TirzepatideGLP-1 & Incretins
Scientist with protective gloves handling test samples in a sterile laboratory environment. — Illustration for a report on the cagrilintide retatrutide combination study in obese rats published in Nature Metabolism
September 17, 2026

Cagrilintide Retatrutide Combination Boosts Weight Loss in Rat Study

A team publishing in Nature Metabolism reports that a cagrilintide retatrutide combination enhanced weight loss and metabolic outcomes in obese male rats, adding rodent evidence to the idea that amylin analogues and incretin agonists work better together. The finding lands while retatrutide itself is still investigational and, separately, while antidoping chemists publish methods for detecting it in human plasma and urine.

RetatrutideGLP-1 & IncretinsSafety & Regulation
Pharmacist with turban organizing shelves in a pharmacy, focused on healthcare. — FDA announcement that the tirzepatide shortage is resolved and compounder policies clarified
September 16, 2026

Tirzepatide Shortage Resolved, FDA Says, With New Compounder Guidance

The US Food and Drug Administration has declared the tirzepatide shortage resolved and issued clarified policies for compounders as national GLP-1 supply stabilizes. Because compounding copies of a commercially available drug is generally permitted only while that drug is in shortage, the determination reaches directly into how many people currently obtain their medication.

TirzepatideCompounding & SupplySafety & Regulation
A medical professional wearing protective clothing writing on a clipboard. — Illustration accompanying a report on GLP-1 after bariatric surgery and the Phase 4 randomized trial now recruiting patients
September 12, 2026

GLP-1 After Bariatric Surgery: Phase 4 Trial Now Recruiting

Two academic randomized trials are now attacking the same unanswered question: what should happen to GLP-1 after bariatric surgery. One is recruiting 150 patients in Missouri; the other, GRABS, has just published its rationale, design and baseline characteristics. For anyone tracking a GLP-1 protocol through a planned surgery, this is the evidence that does not yet exist.

GLP-1 & IncretinsSemaglutideTirzepatide
Healthcare worker in scrubs reviewing patient files with a stamp and clipboard. — Clinical trial registry listing for the NNC0662-0419 phase 2 trial comparing a Novo Nordisk candidate with semaglutide
September 11, 2026

NNC0662-0419 Phase 2 Trial Compares Novo Drug to Semaglutide

A newly posted NNC0662-0419 phase 2 trial record shows Novo Nordisk testing an experimental blood-sugar medicine head-to-head against semaglutide in 270 people with type 2 diabetes. For anyone following what comes after the current generation of GLP-1 drugs, the choice of comparator is the detail worth noting.

SemaglutideGLP-1 & IncretinsTirzepatide
High-resolution x-ray image showing the intricate anatomy of human hands. — Illustration accompanying coverage of the cagrilintide bone density trial comparing cagrilintide, semaglutide and CagriSema
September 10, 2026

Cagrilintide Bone Density Trial Opens With Semaglutide Comparator

A newly posted cagrilintide bone density trial puts an amylin analogue head-to-head with semaglutide and with the CagriSema combination, and its stated purpose is bone health rather than weight. For anyone tracking a GLP-1 or incretin protocol, it is a signal that skeletal outcomes are moving from footnote to primary question.

SemaglutideGLP-1 & IncretinsSafety & Regulation
Healthcare worker in scrubs reviewing patient files with a stamp and clipboard. — Article illustration for the Johns Hopkins Phase 2 tirzepatide binge eating disorder trial listed on ClinicalTrials.gov
September 9, 2026

Tirzepatide Binge Eating Disorder Trial Opens at Johns Hopkins

A Phase 2 tirzepatide binge eating disorder trial run by Johns Hopkins University is listed as recruiting on ClinicalTrials.gov, with 105 planned participants and a three-arm design that pits the dual incretin drug against both placebo and an established binge-eating medication. It is one of the first registered attempts to test whether an incretin therapy does anything for binge eating that is separable from weight loss.

TirzepatideGLP-1 & IncretinsSafety & Regulation
Close-up of a smoked cigarette butt resting on a textured clay surface in outdoor light. — Illustration accompanying coverage of the semaglutide smoking cessation trial now recruiting participants with diabetes
September 8, 2026

Semaglutide Smoking Cessation Trial Opens Recruiting in Diabetes

A new semaglutide smoking cessation trial listed on ClinicalTrials.gov is recruiting 100 participants with diabetes to test the GLP-1 receptor agonist as an add-on to nicotine replacement therapy. It is one of several studies registered or published this week pushing incretin drugs well beyond weight and glucose control.

SemaglutideGLP-1 & IncretinsTirzepatide
Older →
How this page is made. PeptideWiz News covers regulatory actions, published research, and industry developments from a fixed list of primary sources — the FDA, NIH, EMA, ClinicalTrials.gov, PubMed, peer-reviewed journals, and company press rooms. Articles are drafted with AI assistance from those sources, reviewed before publication, and always link to the original. Read the full editorial standards & corrections policy. This is journalism about peptides, not medical advice: it does not recommend any substance, does not state dosages, and is not a substitute for your provider.

The peptide news that mattered, weekly

One email a week with the regulatory actions, trial results, and safety alerts worth knowing. No spam, unsubscribe any time.

Calculate Now